What does tentative FDA approval mean for the $40-a-year HIV prevention shot?

The FDA granted tentative approval on November 2 to Dr. Reddy’s generic lenacapavir, a twice-yearly HIV prevention injection, with a target cost near $40 a year for about 120 low- and middle-income countries versus a roughly $28,000 U.S. branded list price. It cannot be sold in the U.S. while patents remain active — the conditions, stated plainly.

Short answer: on November 2, the U.S. Food and Drug Administration granted tentative approval to Dr. Reddy’s generic version of lenacapavir — a twice-yearly injection that prevents HIV.

Tentative approval means the FDA has judged the generic to meet its standards, but it cannot be sold in the United States while the branded drug’s patents remain in force. The plan is supply for around 120 low- and middle-income countries at a target cost near $40 per person per year, against a U.S. branded list price of about $28,000 a year. Status: conditional, and aimed outside the U.S. for now.Why it matters: prevention only works when people can actually get it.

A shot twice a year removes the daily-pill problem — no bottles to keep, no doses to miss — and long-acting prevention has already changed HIV prevention where it is available. At a small fraction of the branded price, health systems in the countries carrying most of the world’s HIV burden could offer it at a scale the U.S. price never allowed — if manufacturing, registrations and funding follow through.What to take from the announcement:1. It is prevention, not treatment or a cure: lenacapavir injections stop HIV from taking hold in people who do not have it; they do not treat people already living with HIV.2.

“Tentative” is the key word for U.S. readers: nothing in this approval puts a cheaper version on an American pharmacy shelf while the patents stand.3. The $40 figure is a target for eligible countries under access arrangements — not a price an individual can order at today, anywhere.4. Twice a year still means twice a year: the benefit is freedom from daily pills; the requirement is clinics that deliver the shots on schedule.5.

Watch the rollout, not just the approval: registrations in each country, factory output and funding decide whether a headline becomes doses in arms.Pro tip: when a drug story carries a dramatic price comparison, check which country’s price it is and who is allowed to buy at it. The same medicine routinely carries several prices at once, and only one of them may apply to you.Ad’s take: A genuine access milestone for the countries named, with the conditions kept attached — and, for now, no change at a U.S. pharmacy counter.